{'fraction_non_alphanumeric': 0.03125, 'fraction_numerical': 0.014423076923076924, 'mean_word_length': 5.358778625954199, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Heart rate reduction may be a major determinant of vascular tone in esmolol-treated septic shock patients-although still remains to be confirmed!

Over the last decade, the regulation of the autonomic nervous system by β1-adrenoreceptor antagonists in septic shock patients has been the subject of growing literature. In 2013, Morelli et al . published a randomized, controlled, open-label, single-center phase 2 trial investigating the efficacy of intravenous esmolol, a short acting β1-blocker titrated to lower heart rate (HR) in septic shock patients with severe tachycardia. This study found that esmolol was associated with a reduction in HR to the specified target range (80–94 bpm), maintained cardiac output, increased systemic vascular resistances along with a subsequent reduction in norepinephrine dose requirements (1).